The effects of acarbose combined with metformin on inflammatory factors and cellular immune function in patients with type 2 diabetes mellitus
-
摘要: 目的 探讨阿卡波糖联合二甲双胍对2型糖尿病患者的临床疗效及作用机制。 方法 将114例2型糖尿病患者随机分为联合治疗组(n=58)、二甲双胍组(n=56)。二甲双胍组给予二甲双胍治疗,联合治疗组给予阿卡波糖联合二甲双胍治疗。治疗3个月后,比较2组血清炎性因子、T淋巴细胞亚群、血糖控制、不良反应发生率。 结果 联合治疗组血清白细胞介素-6(IL-6)、C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)水平低于二甲双胍组(P<0.05), CD3+、CD4+、CD4+/CD8+高于二甲双胍组, CD8+低于二甲双胍组,差异有统计学意义(P<0.05)。联合治疗组空腹血糖(FPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)低于二甲双胍组,差异有统计学意义(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。 结论 阿卡波糖联合二甲双胍可抑制2型糖尿病患者的炎症反应,并调节其细胞免疫功功能和血糖水平。Abstract: Objective To explore the clinical effect of acarbose combined with metformin for patients with type 2 diabetes mellitus and its mechanism of action. Methods A total of 114 patients with type 2 diabetes were randomly divided into combined treatment group(n=58)and metformin group(n=56). The metformin group was treated with metformin, while the combined treatment group was given acarbose combined with metformin. After 3 months of treatment, serum inflammatory factors, T lymphocyte subsets, blood glucose control and incidence of adverse reactions were compared between the two groups. Results The levels of serum interleukin-6(IL-6), C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)in the combined treatment group were significantly lower than those in the metformin group(P<0.05), CD3+, CD4+, CD4+/CD8+ in the combined treatment group were significantly higher than those in the metformin group, and CD8+ was significantly lower than that in the metformin group(P<0.05). Fasting blood gluscose(FPG), fasting insulin(FINS), Hemoglobin A1c(HbA1c)and homeostasis model assessment of insulin resistance(HOMA-IR)in the combined treatment group were significantly lower than those in the metformin group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Acarbose combined with metformin can inhibit the inflammatory response of patients with type 2 diabetes mellitus, and regulate their cellular immune function and blood glucose level.
-
Keywords:
- type 2 diabetes mellitus /
- acarbose /
- metformin /
- inflammatory factors /
- T lymphocytes
-
-
PAN Q, XU Y, YANG N, et al. Metformin or acarbose treatment significantly reduced albuminuria in patients with newly diagnosed type 2 diabetes mellitus and low-grade albuminuria[J]. Med Sci Monit, 2018, 24: 8941-8949.
OU H T, CHEN Y T, LIU Y M, et al. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan[J]. Diabetes Res Clin Pract, 2016, 116: 14-25.
MOELANDS S V, LUCASSEN P L, AKKERMANS R P, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2018, 12(12): CD005061.
AKASH M S H, REHMAN K, LIAQAT A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus[J]. J Cell Biochem, 2018, 119(1): 105-110.
ABOUZEID S, SHERIF N. Role of alteration in Treg/Th17 cells' balance in nephropathic patients with Type 2 diabetes mellitus[J]. Electron Physician, 2015, 7(8): 1613-1618.
WANG L M, GAO P, ZHANG M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017, 317(24): 2515-2523.
ZHANG Q G, WANG C Q, XUE S, et al. Comparison of acarbose and metformin as add-on therapy to isulin in uncontrolled patients with type 2 diabetes mellitus: A randomized, open-labeled, and parallel group study[J]. Chin J Endocrinol Metab, 2018, 34(9): 755-760.
VOS R C, VAN AVENDONK M J, JANSEN H, et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control[J]. Cochrane Database Syst Rev, 2016, 9(9): CD006992.
张丽菊, 李为民. 阿卡波糖联合二甲双胍治疗2型糖尿病伴高血脂症疗效的回顾性研究[J]. 中国药师, 2017, 20(2): 284-286. ZHANG J, JIN J, LIU J L, et al. A study of the correlation of insulin resistance and leptin with inflammatory factors and vascular endothelial injury in T2DM patients with CHD[J]. Exp Ther Med, 2018, 16(1): 265-269.
HOFMEISTER M. Comment on: efficacy of Omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients[J]. Singapore Med J, 2013, 54(1): 53-53.
PHOSAT C, PANPRATHIP P, CHUMPATHAT N, et al. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: a cross-sectional study[J]. BMC Endocr Disord, 2017, 17(1): 44-52.
蔡凤, 刘钜荣, 范德美, 等. 二甲双胍对2型糖尿病大鼠非酒精性脂肪性肝病相关慢性炎症反应的影响[J]. 实用医学杂志, 2018, 34(12): 1965-1969. SU B L, LIU H X, LI J, et al. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes, 2015, 7(5): 729-739.
曹永, 王宏宇, 徐春. 天芪降糖胶囊联合二甲双胍对2型糖尿病患者白介素6、肿瘤坏死因子α和C反应蛋白的影响[J]. 中国糖尿病杂志, 2015, 23(8): 739-741. KIM S A, Choi H C. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cell[J]. Biochem Biophys Res Commun, 2012, 425(4): 866-872.
PANG N, CHEN K, PENG H J, et al. Effect of Acarbose Combined with Metformin on Related Indexes of Patients with Type 2 Diabetes[J]. China Pharmacy, 2017, 28(27): 3774-3777.
SHEIKH V, ZAMANI A, MAHABADI-ASHTIYANI E, et al. Decreased regulatory function of CD4+CD25+CD45RA+ T cells and impaired IL-2 signalling pathway in patients with type 2 diabetes mellitus[J]. Scand J Immunol, 2018, 88(4): e12711.
DU J, LIANG L, FANG H, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase Ⅳ open-label randomized controlled study(the SMART study)[J]. Diabetes Obes Metab, 2017, 19(11): 1513-1520.
MAHMOUD F F, HAINES D, DASHTI A A, et al. Correlation between heat shock proteins, adiponectin, and T lymphocyte cytokine expression in type 2 diabetics[J]. Cell Stress Chaperones, 2018, 23(5): 955-965.
KIM E K, LEE S H, JHUN J Y, et al. Metformin prevents fatty liver and improves balance of white/brown adipose in an obesity mouse model by inducing FGF21[J]. Mediators Inflamm, 2016, 2016: 5813030.
LEE S Y, LEE S H, YANG E J, et al. Metformin ameliorates inflammatory bowel disease by suppression of the STAT3 signaling pathway and regulation of the between Th17/treg balance[J]. PLoS One, 2015, 10(9): e0135858.
GAO L Y, LIU J Q, YANG S J, et al. Effect on T cell subsets and function of isletβ cells of levemir combined with acarbose in elder patients with early-onset type 2 Diabetes Mellitus[J]. 海南医科大学学报: 英文版, 2017, 23(2): 74-77.
计量
- 文章访问数: 305
- HTML全文浏览量: 98
- PDF下载量: 17
下载:
苏公网安备 32100302010246号